UNSPSC 51102854: Hydrocortisone/iodoquinol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102854 Hydrocortisone/iodoquinol is a Commodity code that nominally names a specific pharmaceutical combination product, but the recent state and local opportunities tagged under it reflect broader pharmaceutical supply procurement — notably naloxone (an opioid antagonist), drug deactivation systems, and antibiotics such as doxycycline and ciprofloxacin. State and local health departments, county health authorities, and public health agencies use this code to solicit emergency pharmaceuticals, public-health medication supplies, and related medical products. The purchasing pattern suggests the code serves as a catch-all for pharmaceutical warehouse and emergency-supply procurement where specific UNSPSC codes for individual products may not exist or are not consistently applied by issuing bodies. Issuing bodies include state departments of public health and county health authorities; the recent activity shows both state-level coordination through consortium purchasing (MMCAP Infuse) and direct county procurement by smaller jurisdictions.

Recent opportunities include an Illinois Department of Public Health piggyback award through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, totaling $2,999,999.11 over three years for doxycycline hyclate and ciprofloxacin hydrochloride tablets (completed IFB), and a Seminole County, Florida IFB released June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (due July 26, 2023—note the due date appears erroneous in the source). Activity concentrates in the Southeast and Midwest; Illinois and Florida account for the recent solicitations named. Consortium purchasing vehicles such as MMCAP Infuse appear to dominate larger state-level pharmaceutical procurement, while county health authorities pursue direct procurement for emergency-response supplies.